In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on CVRx (CVRX – Research Report), with a price target of $35.00. The company’s shares closed last Friday at $14.69.
Takkinen covers the Healthcare sector, focusing on stocks such as ClearPoint Neuro, Silk Road Medical, and Inotiv. According to TipRanks, Takkinen has an average return of 0.8% and a 37.99% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVRx with a $33.33 average price target.
Based on CVRx’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $11.31 million and a GAAP net loss of $9.16 million. In comparison, last year the company earned a revenue of $7.18 million and had a GAAP net loss of $10.54 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVRx (CVRX) Company Description:
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
